2020 is such a special year that we almost forgot to celebrate the 10th anniversary of IPStudies patent analytics activities… the local party is postponed to a later, post-COVID date, but we’d still like to take a look back at our first ten years of practice. Back in September 2010, patent mining and landscaping tools were still in their infancy, limited to basic quantitative counts over time and classes. Having experimented the benefit of using patent analytics data to guide R&D as well as M&A development choices in the high-tech corporate world, IPStudies’s founder, Corinne Le Buhan, envisioned the need to bring this information to Swiss technology “grown-ups” as early as possible in their product development cycle. By going beyond the extraction of austere lists of patent numbers to visually highlight their development context, it becomes much easier to benchmark and thus optimize the IP development positioning for companies exposed to highly competitive environments.
Continue readingTag: IPStudies
Myths and realities on DuPont CRISPR assets
On the agriculture side, IAM just published this week some basic quantitative data analytics spotting DuPont as the leader in CRISPR patent assets. The IAM interview also highlighted some questions about the licensing position of DuPont in the CRISPR patent battle. This was quite surprising to read for us as this information has been publicly known since 2014 and regularly compiled in both our patent and licensing landscapes. Let’s take a closer scrutiny into the DuPont CRISPR assets. In our monitoring of licensing data since 2014, we have actually spotted DuPont Pioneer as one of the earliest player to position their licensing-in in a very strategic way:
US inventor veterans at Intellectual Ventures are inventing around CRISPR gene editing
As both patent analysts and strategists, we like to look into the “weak signals” hidden behind the main trends of our landscapes, such as emerging design around solutions, original applications and new unexpected players entering the field.
In our latest update of our CRISPR patent landscape, we were surprised to discover a PCT patent application from a couple of senior inventors from Nathan Myhrvold’s team at Intellectual Ventures.
Continue reading